Duggingen, Switzerland

Stefan Abrecht

This inventor holds 5 USPTO granted patents and 9 published patent applications and 2 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2000-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Abrecht. Retrieved from https://idiyas.com/inventor/stefan-abrecht

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

% Patents Active = 40.0

 

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2000-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Stefan Abrecht from Duggingen, CH

Introduction:

Stefan Abrecht, a talented inventor hailing from Duggingen, CH, has made significant contributions to the field of pharmaceuticals with a total of 5 patents to his name. His innovative work has sparked advancements in the treatment and prevention of diseases associated with DPP IV.

Latest Patents:

1. **Process for the preparation of pyrido[2,1-a] isoquinoline derivatives**: Stefan's patented process focuses on the creation of pyrido[2,1-a]isoquinoline derivatives, crucial compounds for combating diseases linked to DPP IV. These derivatives offer promising therapeutic benefits and open new avenues in the pharmaceutical industry.

2. **Salt and polymorphs of a DPPIV inhibitor**: Another groundbreaking invention by Stefan is (S)-1-{[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile mesylate and its crystalline polymorphs. These compounds exhibit superior properties compared to existing alternatives and hold immense potential as a medicinal solution for DPP-IV related disorders.

Career Highlights:

Stefan Abrecht is a distinguished member of the research team at Hoffmann-La Roche Inc., a renowned pharmaceutical company known for its cutting-edge innovations. His expertise and dedication have played a pivotal role in shaping the company's success and establishing it as a leader in the healthcare industry.

Collaborations:

Throughout his career, Stefan has collaborated closely with esteemed colleagues such as Jean-Michel Adam and Alec Fettes. Together, they have engaged in collaborative research, shared insights, and collectively contributed to the development of new and impactful pharmaceutical solutions.

Conclusion:

In conclusion, Stefan Abrecht's remarkable ingenuity and unwavering commitment to scientific excellence have left an indelible mark on the field of pharmaceuticals. His pioneering inventions not only enhance our understanding of DPP-IV related diseases but also offer hope for a healthier future. Stefan's collaborative spirit and innovative mindset continue to inspire breakthroughs that shape the landscape of modern medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…